Skip to main content
Frontiers in Microbiology logoLink to Frontiers in Microbiology
. 2019 Jan 4;9:3220. doi: 10.3389/fmicb.2018.03220

Identification of Specific Oral and Gut Pathogens in Full Thickness Colon of Colitis Patients: Implications for Colon Motility

Vasudevan Dinakaran 1,, Sammed N Mandape 2,, Kristina Shuba 1, Siddharth Pratap 2, Shruti S Sakhare 2, Mohammad Ali Tabatabai 3, Duane T Smoot 4, Cherae M Farmer-Dixon 1, Lakshmyya N Kesavalu 5, Samuel Evans Adunyah 6, Janet Hayes Southerland 7, Pandu R Gangula 1,*
PMCID: PMC6330997  PMID: 30666239

Abstract

Impaired colon motility is one of the leading problems associated with inflammatory bowel disease (IBD). An expanding body of evidence supports the role of microbiome in normal gut function and in progression of IBD. The objective of this work is to determine whether diseased full thickness colon specimens, including the neuromuscular region (critical for colon motility function), contain specific oral and gut pathogens. In addition, we compared the differences in colon microbiome between Caucasians (CA) and African Americans (AA). Thirty-nine human full thickness colon (diseased colon and adjacent healthy colon) specimens were collected from Crohn's Colitis (CC) or Ulcerative Colitis (UC) patients while they underwent elective colon surgeries. We isolated and analyzed bacterial ribosomal RNA (rRNA) from colon specimens by amplicon sequencing of the 16S rRNA gene region. The microbiome proportions were quantified into Operational Taxonomic Units (OTUs) by analysis with Quantitative Insights Into Microbial ecology (QIIME) platform. Two hundred twenty-eight different bacterial species were identified by QIIME analysis. However, we could only decipher the species name of fifty-three bacteria. Our results show that proportion of non-detrimental bacteria in CC or UC colon samples were altered compared to adjacent healthy colon specimens. We further show, for the first time in full thickness colon specimens, that microbiome of CC and UC diseased specimens is dominated by putative oral pathogens belonging to the Phyla Firmicutes (Streptococcus, Staphylococcus, Peptostreptococcus), and Fusobacteria (Fusobacterium). In addition, we have identified patterns of differences in microbiome levels between CA and AA specimens with potential implications for health disparities research. Overall, our results suggest a significant association between oral and gut microbes in the modulation of colon motility in colitis patients.

Keywords: colitis, colon motility, nitric oxide (NO), antioxidants, oral microbiome, operational taxonomic units (OTUs), gut microbiome

Introduction

Inflammatory bowel disease (IBD) is comprised of Crohn's disease / Crohn's colitis (CC) and Ulcerative colitis (UC). The term Colitis, refers to general inflammation of the inner lining of the colon arising from numerous underlying causes including idiopathic infection, IBD (either CC or UC), ischemic colitis, allergic reactions, and/or microscopic colitis. Distally, gingivitis, and periodontal disease are chronic inflammatory gum diseases associated with orange, red, yellow, purple, and green complex bacterial infections in sub-gingival areas of oral cavity (Popova et al., 2013).

Previous studies have shown that periodontal disease (PD) is a significant risk factor and contributor to many systemic diseases, including IBD (Vavricka et al., 2013). Several factors including genetic, dietary, and environmental factors could influence the pathogenesis of microbiome (oral and gut) which in turn may increase the incidence of periodontitis and IBD (Lira-Junior and Figueredo, 2016; Agossa et al., 2017). In addition, Porphyromonas gingivalis known to cause PD altered the gut microbiota leading to increased gut epithelial permeability and endotoxemia, which causes systemic inflammation (Hajishengallis, 2015). In addition, many earlier studies have shown intestinal colonization of oral bacteria in the pathogenesis of IBD (Strauss et al., 2011; Atarashi et al., 2017).

Innumerable number of studies have shown that the gut microbiome including Phyla Proteobacteria, Firmicutes, and Bacteroidetes contribute to normal gut function (Mariat et al., 2009; Koliada et al., 2017; Walker et al., 2018; Zhao et al., 2018). Colon motility is mainly regulated by neuromuscular portion of the colon and this was shown to be impaired in colitis patients; putatively due to a reduction in neuronal nitric oxide (NO) synthase (nNOS) protein expression and/or neuronal degeneration (Bassotti et al., 2014; Gangula et al., 2017). Previous studies have analyzed the microbiome in feces and/or colon mucosal biopsy specimens of colitis patients (Gibson et al., 1991; Bibiloni et al., 2006). However, the relationship/interaction between oral and gut bacteria in the development and/or exacerbation of inflammatory disease in the colon (containing neuromuscular tissue) was under studied. In addition, data is limited on how oral bacteria interact with and influence the large intestinal flora, thereby contributing to colitis. Since motility of the colon is impaired in colitis patients and neuromuscular tissue play a role in the motility function (Geboes and Collins, 1998; Poli et al., 2001), we hypothesize that the interaction between oral and gut microbiome may play a significant role in the inflammatory processes associated with the development and progression of colitis seen in certain patient populations. Furthermore, we hypothesize that difference in microbiome may exist between CA and AA colitis patients, potentially contributing to health disparities in IBD.

Methods

Ethics Statement

The participants provided both written and verbal informed consent to Collaborative Human Tissue Networking (CHTN) Consortium to collect specimens while they underwent elective colon surgeries.

Collection of Specimens

Frozen full thickness colon specimens were obtained from Cooperative Human Tissue Networking (CHTN). Thirty-nine human full thickness colon (moderate to severe diseased colon and adjacent healthy colon) specimens were collected from CC and UC male and female patients (ages between 18 and 75 years old) while they underwent elective colon surgeries. The specimens include Ulcerative (n = 13), Crohn's (n = 13) and adjacent healthy (n = 13) specimens. Characteristics of participants included Caucasians (CA) (n = 30) and African Americans (AA) (n = 9). CC male and female patients presented with symptoms like fever, fatigue, diarrhea, blood in stool, mouth sores, abdominal cramping, and pain around the anus, reduced appetite, and weight loss. While UC male and female patients presented with additional signs like rectal pain, rectal bleeding, and inability to defecate despite urgency.

Extraction of DNA, Amplification of 16S rRNA Gene and Amplicon Sequencing

DNA extraction and microbial analysis were performed in the University of North Carolina at Chapel Hill School of Medicine Microbiome Core Facility (UNC: MC). We identified a conserved region of the 16S rRNA gene of 550 bp to amplify. This encompassed variable regions V3–V4 from the colon genomic DNA using primers 16S rRNA-F 5′-AGAGTTTGATCCTGGCTCAG-3′and 16S rRNA-R 5′-GCTGCCTCCCGTAGGAGT-3′ and overhang adapter sequences appended to the primer pair for compatibility with Illumina index and sequencing adapters. Briefly, each 16SrRNA amplicon was purified using AMPure XP reagent (Beckman Coulter, Indianapolis, IN, USA). Specifically, each sample was amplified using a limited cycle PCR program, adding Illumina sequencing adapters and optional dual-index barcodes [index 1(i7) and index 2(i5)] (Illumina, San Diego, CA, USA) to the amplicon target. The final libraries were purified using AMPure XP reagent, quantified and normalized prior to pooling. The DNA library pool was denatured with NaOH, diluted with hybridization buffer and heat denatured before loading on to the MiSeq reagent cartridge and to the MiSeq instrument (Illumina). The standard Illumina paired-end 250 base pair (PE250) protocol was used for sequencing the16S rRNA amplicons (Illumina, CA, USA).

Processing of Sequence Reads

Data was analyzed and microbial proportions using Operational Taxonomic Units (OTUs) were determined using Quantitative Insights Into Microbial ecology (QIIME) pipeline (Caporaso et al., 2010a) in the Meharry Medical College Bioinformatics Core. Briefly, generated raw reads were preprocessed for adapter removal. Processed sequence reads were obtained as fastq files and were converted into fasta, quality and flow files using Mothur package (Schloss et al., 2009). The initial number of fasta sequences obtained were 31,09,793. First, the fasta files were cleaned of host reads by mapping on to 9 mm mouse genome. Then, the primer sequences and barcode sequences were removed, demultiplexed and quality filtered. The number of high quality sequences remaining after quality filtering was 16,64,769. The OTUs were picked by de novo strategy. The high quality sequences were clustered at 97% identity using UCLUST inbuilt in QIIME pipeline to generate 3994 OTUs and taxonomy was assigned to OTU representative sequences using UCLUST (Edgar, 2010). The picked sequences were aligned using PyNAST aligner (Caporaso et al., 2010b). The chimeric sequences and singleton OTUs were removed using ChimeraSlayer (Haas et al., 2011). We constructed a phylogenetic tree for the sequences using FastTree version 2.1.3 (data not shown) (Price et al., 2010). Next, an OTU table was constructed and taxa were summarized using the 894 OTUs obtained from QIIME pipeline. α-diversity metrics was computed using Chao1 (abundance-based richness estimator) and Shannon analysis (diversity index) and Rarefaction plots were constructed (data not shown). β-diversity metrics was computed using weighted and unweighted Principal Coordinates Analysis (PCoA) (data not shown) (Gower, 2005). A Taxonomic Summary Bar plot showing OTUs assigned to Phyla-level taxonomy per sample was subsequently constructed (Figure 1). Bar Plots showing the relative abundance of bacteria at the Phyla-level between races, diseased tissue and healthy tissue groups is shown in Figure 3. Sample-specific sequences were deposited in the MGRAST database (accession number: b3b851ba2c6d676d343739393937332e33) and was assigned an MG-RAST project ID (mgs675214) (Keegan et al., 2016). In addition, sample-specific sequences were deposited in the NCBI (BioProject: PRJNA496071).

Figure 1.

Figure 1

Summary of major bacterial taxa contributing to the communities detected in the 39 specimens at the Phylum level in the colitis and adjacent healthy specimen groups. Specimens are categorized into adjacent healthy colon (n = 13), Ulcerative colitis (UC, n = 13), and Crohn's colitis (CC, n = 13). Data represented are the relative abundances (%) of each phylum identified in each specimen.

The pathogenic and beneficial oral and gut bacteria were identified using the NCBI Genome database (https://www.ncbi.nlm.nih.gov/genome/). This analysis was performed to assess the pathogenic and healthy bacterial proportions in human full thickness colon specimens (Tables 13).

Table 1.

Functions and proportions of specific pathogenic Oral bacteria colonized in full thickness colon specimens.

Sl. No. Bacteria genus Bacteria species Proportion (%) Bacteria phylum Function in IBD NCBI genome database link
ADJACENT HEALTHY COLON
1 Prevotella stercorea 2.3 Bacteroidetes Alters mucosal microbiota in the colon of patients with IBD H
2 Prevotella Other 0.3 Bacteroidetes A microbial signature of Crohn's disease GS
3 Gemella s__ 0.1 Firmicutes Microbiome in New-Onset Crohn's Disease CP
4 Staphylococcus sciuri 0.1 Firmicutes Develops intestinal inflammation in acute and chronic colitis I
5 Staphylococcus aureus 0.6 Firmicutes Causes Crohn's disease AU
6 Abiotrophia s__ 0.1 Firmicutes Causes fecal microbial dysbiosis in IBD CS
7 Lactobacillus zeae 1.9 Firmicutes Maintains remission of ulcerative colitis A
8 Lactobacillus s__ 0.4 Firmicutes Maintains remission of ulcerative colitis CW
9 Lactococcus s__ 0.7 Firmicutes Used in the treatment of Crohn's disease CX
10 Peptostreptococcus anaerobius 11.6 Firmicutes Causes dysbiosis in IBD AW
11 Peptostreptococcus s__ 0.5 Firmicutes Causes gut microbiota dysbiosis in IBD DR
12 Selenomonas s__ 0.2 Firmicutes Causes dysbiosis in colorectal cancer EB
13 Eubacterium dolichum 1.0 Firmicutes Causes dysbiosis of the intestinal microbiota AL
14 Fusobacterium s__ 2.2 Fusobacteria Identified from colonic biopsies of IBD patients EN
15 Pseudomonas alcaligenes 1.8 Proteobacteria Identified in the gut microbiota of IBD AX
16 Pseudomonas s__ 0.1 Proteobacteria Causes infection in Children with Early-onset Crohn's Disease GG
17 Pseudomonas Other 0.2 Proteobacteria Gut microbe in children with early onset Crohn's disease HR
18 Corynebacterium durum 0.1 Actinobacteria Gut microbe in IBD patients AK
19 Corynebacterium s__ 0.8 Actinobacteria Causes experimental colitis BI
20 Pseudoramibacter_Eubacterium s__ 1.6 Firmicutes Metabolizes Linoleic acid in the Gut DF
DISEASED COLON (ULCERATIVE COLITIS)
1 Prevotella stercorea 1.0 Bacteroidetes Alters mucosal microbiota in the colon of patients with IBD H
2 Prevotella s__ 0.3 Bacteroidetes A microbial signature of Crohn's disease BZ
3 Prevotella Other 0.3 Bacteroidetes A microbial signature of Crohn's disease GS
4 Staphylococcus aureus 0.3 Firmicutes Causes Crohn's disease AU
5 Lactobacillus zeae 7.6 Firmicutes Maintains remission of ulcerative colitis A
6 Lactobacillus s__ 0.3 Firmicutes Maintains remission of ulcerative colitis CW
7 Lactococcus s__ 0.6 Firmicutes Used in the treatment of Crohn's disease CX
8 Peptostreptococcus anaerobius 12.7 Firmicutes Causes dysbiosis in IBD AW
9 Peptostreptococcus s__ 0.3 Firmicutes Causes gut microbiota dysbiosis in IBD DR
10 Selenomonas s__ 0.1 Firmicutes Causes dysbiosis in colorectal cancer EB
11 Eubacterium dolichum 0.5 Firmicutes Causes dysbiosis of the intestinal microbiota AL
12 Pseudoramibacter_ Eubacterium s__ 1.9 Firmicutes Metabolizes Linoleic acid in the Gut DF
13 Fusobacterium s__ 3.0 Fusobacteria Identified from colonic biopsies of IBD patients EN
14 Pseudomonas alcaligenes 0.4 Proteobacteria Identified in the gut microbiota of IBD AX
15 Pseudomonas s__ 0.8 Proteobacteria Infection in Children with Early-onset Crohn's Disease GG
16 Aggregatibacter s__ 1.4 Proteobacteria Causes fungal microbiota dysbiosis in IBD
17 Corynebacterium s__ 1.0 Actinobacteria Causes experimental colitis BI
DISEASED COLON (CROHN'S COLITIS)
1 Prevotella tannerae 0.2 Bacteroidetes Prevalent in colitis F
2 Prevotella stercorea 3.3 Bacteroidetes Alters mucosal microbiota in the colon of patients with IBD H
3 Prevotella melaninogenica 0.4 Bacteroidetes Gut microbiome biomarker in ankylosing spondylitis U
4 Prevotella Other 3.3 Bacteroidetes A microbial signature of Crohn's disease GS
5 Gemella s__ 0.1 Firmicutes Microbiome in New-Onset Crohn's Disease CP
6 Staphylococcus sciuri 0.1 Firmicutes Develops intestinal inflammation in acute and chronic colitis I
7 Staphylococcus aureus 0.5 Firmicutes Causes Crohn's disease AU
8 Abiotrophia s__ 0.2 Firmicutes Causes fecal microbial dysbiosis in IBD CS
9 Lactobacillus zeae 6.8 Firmicutes Maintains remission of ulcerative colitis A
10 Lactobacillus reuteri 0.1 Firmicutes Prevents colitis as a probiotic M
11 Lactobacillus s__ 0.6 Firmicutes Maintains remission of ulcerative colitis CW
12 Lactococcus s__ 0.7 Firmicutes Used in the treatment of Crohn's disease CX
13 Peptostreptococcus anaerobius 4.0 Firmicutes Causes dysbiosis in IBD AW
14 Peptostreptococcus s__ 0.1 Firmicutes causes gut microbiota dysbiosis in IBD DR
15 Selenomonas s__ 0.4 Firmicutes Causes dysbiosis in colorectal cancer EB
16 Eubacterium dolichum 0.8 Firmicutes Causes dysbiosis of the intestinal microbiota AL
17 Pseudoramibacter_ Eubacterium s__ 1.3 Firmicutes Metabolizes Linoleic acid in the Gut DF
18 Fusobacterium s__ 2.4 Fusobacteria Identified from colonic biopsies of IBD patients EN
19 Pseudomonas alcaligenes 0.8 Proteobacteria Identified in the gut microbiota of IBD AX
20 Pseudomonas s__ 1.0 Proteobacteria Infection in Children with Early-onset Crohn's Disease GG
21 Corynebacterium durum 0.2 Actinobacteria Gut microbe in IBD patients AK
22 Corynebacterium s__ 0.1 Actinobacteria Causes experimental colitis BI
23 Pyramidobacter piscolens 0.1 Synergistetes Oral bacteria in IBD P

Specific Information of functions was adapted from NCBI Genome Database (https://www.ncbi.nlm.nih.gov/genome/).

The bacterial species that could not be identified at the genus level are mentioned as g___ and the bacterial species that could not be identified at the species level are mentioned as s___.

Table 3.

Functions and proportions of specific pathogenic Gut bacteria colonized in full thickness colon specimens.

Sl. No. Bacteria genus Bacteria species Proportion (%) Bacteria phylum Function in IBD NCBI Genome database link
ADJACENT HEALTHY COLON
1 Ochrobactrum s__ 0.1 Proteobacteria Causes early bacterial dependent induction of inducible nitric oxide synthase (iNOS) in epithelial cells in experimental colitis EU
2 Sphingomonas s__ 0.2 Proteobacteria Tissue associated intestinal microflora FF
3 Burkholderia s__ 1.2 Proteobacteria causes dysfunction of GALT and gut flora in IBD FI
4 Acinetobacter rhizosphaerae 0.3 Proteobacteria Identified gut bacteria in IBD K
5 Acinetobacter lwoffii 0.3 Proteobacteria gut bacteria in multiple sclerosis patients W
6 Stenotrophomonas geniculata 1.2 Proteobacteria Identified gut bacteria in IBD AG
7 Staphylococcus sciuri 0.1 Firmicutes Develops intestinal inflammation in acute and chronic colitis I
8 Staphylococcus aureus 0.6 Firmicutes Causes Crohn's disease AU
9 Lactobacillus zeae 1.9 Firmicutes Maintains remission of ulcerative colitis A
10 Lactobacillus s__ 0.4 Firmicutes Maintains remission of ulcerative colitis CW
11 Lactococcus s__ 0.7 Firmicutes Used in the treatment of Crohn's disease CX
12 Pseudomonas alcaligenes 1.8 Proteobacteria Identified in the gut microbiota of IBD AX
13 Pseudomonas s__ 0.1 Proteobacteria Infection in Children with Early-onset Crohn's Disease GG
14 Pseudomonas Other 0.2 Proteobacteria Gut microbe in children with early onset Crohn's disease HR
15 Bacillus s__ 0.2 Firmicutes Increases cytokine levels in IBD CL
16 Bacteroides Other 0.1 Bacteroidetes Commensal bacteria that induces colitis GR
17 Microbacterium maritypicum 0.1 Actinobacteria Fecal microbiome in Obesity V
18 Eggerthella lenta 0.8 Actinobacteria Causes bacteremia in Crohn's disease patient AA
19 Brevundimonas diminuta 0.1 Proteobacteria Identified in the adult fecal microbiota of allergy patients AO
20 Propionibacterium acnes 5.3 Actinobacteria Intestinal microbe in Liver disease BA
21 Methanobrevibacter s__ 0.7 Euryarchaeota Identified in the gut of IBD BB
22 g__ s__ 2.4 Acidobacteria Identified in the gut microbiome of Type 2 Diabetes patients BD
23 g__ s__ 1.1 Actinobacteria Identified in gut microbiota in IBD BF
24 Actinomyces s__ 0.1 Actinobacteria Identified in Abdominopelvic actinomycosis involving the GIT BG
25 Varibaculum s__ 0.2 Actinobacteria Identified in the gut of a premature infant BH
26 Microbacterium s__ 0.1 Actinobacteria Identified in the duodenum of children with ulcerative colitis BK
27 g__ s__ 0.2 Actinobacteria Identified in fecal microbiota of pediatric IBD patients BP
28 Atopobium s__ 0.1 Actinobacteria Altered intestinal microbiota in Crohn's disease BR
29 Slackia s__ 0.2 Actinobacteria Human gut bacteria in Multiple Sclerosis BS
30 g__ s__ 0.1 Bacteroidetes Characterized in intestinal biopsies in IBD patients CB
31 g__ s__ 0.1 Bacteroidetes Human gut microbe in Obesity and IBD CC
32 Cloacibacterium s__ 1.1 Bacteroidetes Identified in the rectum of human colorectal adenoma patients CG
33 g__ s__ 0.2 Cyanobacteria Identified in the gut microbiome of IBD patients CI
34 g__ s__ 0.6 Firmicutes Causes microbiota dysbiosis in IBD CO
35 g__ s__ 0.7 Firmicutes A microbial signature of Crohn's disease DB
36 Clostridium s__ 0.9 Firmicutes Causes infection of the gut in IBD DE
37 Dorea s__ 0.1 Firmicutes Causes dysfunction of the intestinal microbiome in IBD DJ
38 Lachnospira s__ 0.1 Firmicutes Gut bacteria in Crohn's disease patients DK
39 Ruminococcus s__ 0.1 Firmicutes Dominant in gut microbiome of IBD patients DO
40 g__ s__ 0.2 Firmicutes Gut microbe in IBD DP
41 g__ s__ 0.6 Firmicutes A microbial signature of Crohn's disease DQ
42 Anaerotruncus s__ 0.2 Firmicutes Tissue associated intestinal microflora DT
43 Oscillospira s__ 0.4 Firmicutes Gut microbe in IBD patients DU
44 Ruminococcus s__ 0.7 Firmicutes Dominant in gut microbiome of IBD patients DV
45 g__ s__ 0.4 Firmicutes Gut microbe underlying the onset of IBD DW
46 Acidaminococcus s__ 1.3 Firmicutes Gut microbe in IBD DX
47 Phascolarctobacterium s__ 1.9 Firmicutes Causes dysfunction of the intestinal microbiome in IBD DZ
48 Schwartzia s__ 0.5 Firmicutes causes fecal microbial dysbiosis in IBD EA
49 g__ s__ 0.2 Firmicutes A microbial signature of Crohn's disease EC
50 Anaerococcus s__ 1.3 Firmicutes Microbe in Inflammatory Pouch Complications EE
51 Finegoldia s__ 0.3 Firmicutes Intestinal microbe in colorectal cancer EF
52 g__ s__ 0.3 Firmicutes Gut microbe in GI diseases EI
53 Bulleidia s__ 0.1 Firmicutes Fecal-associated and mucosalassociated microbiota in irritable bowel syndrome patients EJ
54 Coprobacillus s__ 0.3 Firmicutes Alters Gut Microbiota in Psoriatic Arthritis EL
55 Leptotrichia s__ 0.7 Fusobacteria Causes gut mucosal inflammation in Rheumatoid arthritis patients EO
56 g__ s__ 4.2 Proteobacteria Intestinal microbe in children with severe and complicated acute viral gastroenteritis EV
57 Methylobacterium s__ 0.1 Proteobacteria Causes microbial dysbiosis in pediatric Crohn's disease EW
58 g__ s__ 0.1 Proteobacteria Intestinal microbe in children with severe and complicated acute viral gastroenteritis EX
59 g__ s__ 1.2 Proteobacteria Involved in host-microbial cross talk in IBD FG
60 Lautropia s__ 0.3 Proteobacteria causes fecal microbial dysbiosis in IBD FJ
61 g__ s__ 0.1 Proteobacteria Fecal and mucosa associated microbe in IBD FK
62 Citrobacter s__ 0.1 Proteobacteria Gut microbe in newly diagnosed with treatment-naïve Crohn's disease patients FY
63 Halomonas s__ 1.4 Proteobacteria Intestinal microflora in chronic kidney disease GB
64 g__ s__ 0.1 Proteobacteria Microbe in colon tissue from IBD subjects GE
65 g__ s__ 0.1 Proteobacteria bacteria in human Ulcerative Colitis patients GH
66 Other Other 0.1 Actinobacteria Alters fecal microbiota in pediatric IBD patients GO
67 Other Other 3.6 Firmicutes gut microbe in experimental colitis GT
68 Other Other 12.5 Firmicutes Fecal and mucosa associated microbe in IBD GW
69 Weissella Other 0.2 Firmicutes Gut microbe in IBD patients GX
70 Other Other 0.1 Proteobacteria Fecal and mucosa associated microbe in IBD HL
71 Other Other 0.1 Proteobacteria Involved in host-microbial cross talk in IBD HM
DISEASED COLON (ULCERATIVE COLITIS)
1 Ochrobactrum s__ 0.1 Proteobacteria Causes early bacterial dependent induction of inducible nitric oxide synthase (iNOS) in epithelial cells in experimental colitis EU
2 Delftia s__ 0.1 Proteobacteria Fecal and mucosa associated microbe in IBD FM
3 Sphingomonas s__ 0.5 Proteobacteria Tissue associated intestinal microflora FF
4 Burkholderia s__ 0.2 Proteobacteria Causes dysfunction of GALT and gut flora in IBD FI
5 Acinetobacter rhizosphaerae 0.7 Proteobacteria Identified gut microbe in IBD K
6 Acinetobacter lwoffii 0.1 Proteobacteria Gut bacteria in multiple sclerosis patients W
7 Acinetobacter s__ 0.5 Proteobacteria Tissue associated intestinal microflora GF
8 Stenotrophomonas geniculata 0.1 Proteobacteria Identified gut microbe in IBD AG
9 Enterococcus s__ 0.8 Firmicutes Induces experimental IBD CV
10 Staphylococcus sciuri 0.1 Firmicutes Develops intestinal inflammation in acute and chronic colitis I
11 Staphylococcus aureus 0.6 Firmicutes Causes Crohn's disease AU
12 Lactobacillus zeae 1.9 Firmicutes Maintains remission of ulcerative colitis A
13 Lactobacillus s__ 0.4 Firmicutes Maintains remission of ulcerative colitis CW
14 Lactococcus s__ 0.7 Firmicutes used in the treatment of Crohn's disease CX
15 Pseudomonas alcaligenes 1.8 Proteobacteria Identified in the gut microbiota of IBD AX
16 Pseudomonas s__ 0.1 Proteobacteria Infection in Children with Early-onset Crohn's Disease GG
17 Pseudomonas Other 0.2 Proteobacteria Gut microbe in children with early onset Crohn's disease HR
18 Bacillus s__ 0.1 Firmicutes Increases cytokine levels in IBD CL
19 Bacteroides caccae 0.1 Bacteroidetes Identified in the gut of ulcerative colitis patients AS
20 Bacteroides Other 0.2 Bacteroidetes Commensal bacteria that induces colitis GR
21 Blautia producta 0.1 Firmicutes Gut microbe in Obesity and IBD N
22 Faecalibacterium prausnitzii 0.1 Firmicutes Gut microbe in Crohn's disease patients O
23 Microbacterium maritypicum 0.1 Actinobacteria Fecal microbiome in Obesity V
24 Eggerthella lenta 5.1 Actinobacteria Causes bacteremia in Crohn's disease patient AA
25 Propionibacterium acnes 2.8 Actinobacteria Intestinal microbe in Liver disease BA
26 Methanobrevibacter s__ 0.3 Euryarchaeota Identified in the gut of IBD BB
27 g__ s__ 1.8 Acidobacteria Identified in the gut microbiome of Type 2 Diabetes patients BD
28 g__ s__ 0.3 Actinobacteria Identified in gut microbiota in IBD BF
29 Adlercreutzia s__ 0.2 Actinobacteria Causes dysbiosis in IBD patients BQ
30 Slackia s__ 0.2 Actinobacteria Alters human gut microbiome in Multiple Sclerosis BS
31 g__ s__ 0.8 Bacteroidetes Identified in gut microbiome of IBD patients CA
32 g__ s__ 0.4 Bacteroidetes Characterized in intestinal biopsies in IBD patients CB
33 g__ s__ 0.1 Bacteroidetes Human gut microbe in Obesity and IBD CC
34 Cloacibacterium s__ 0.4 Bacteroidetes Identified in the rectum of human colorectal adenoma patients CG
35 g__ s__ 0.1 Firmicutes Causes microbiota dysbiosis in IBD CO
36 g__ s__ 0.1 Firmicutes Gut microbe in IBD DA
37 g__ s__ 1.7 Firmicutes A microbial signature of Crohn's disease DB
38 Clostridium s__ 0.8 Firmicutes Causes infection of the gut in IBD DE
39 Dorea s__ 0.1 Firmicutes Causes dysfunction of the intestinal microbiome in IBD DJ
40 Lachnospira s__ 0.3 Firmicutes gut bacteria in Crohn's disease patients DK
41 Ruminococcus s__ 0.1 Firmicutes Dominant in gut microbiome of IBD patients DO
42 g__ s__ 0.3 Firmicutes A microbial signature of Crohn's disease DQ
43 Oscillospira s__ 0.1 Firmicutes Gut microbe in IBD patients DU
44 Ruminococcus s__ 0.9 Firmicutes Dominant in gut microbiome of IBD patients DV
45 g__ s__ 0.3 Firmicutes Gut microbe underlying the onset of IBD DW
46 Acidaminococcus s__ 1.1 Firmicutes Gut microbe in IBD DX
47 Phascolarctobacterium s__ 2.2 Firmicutes Causes dysfunction of the intestinal microbiome in IBD DZ
48 Schwartzia s__ 0.5 Firmicutes Causes fecal microbial dysbiosis in IBD EA
49 Anaerococcus s__ 0.6 Firmicutes Microbe in Inflammatory Pouch Complications EE
50 Finegoldia s__ 0.3 Firmicutes Intestinal microbe in colorectal cancer EF
51 g__ s__ 0.6 Firmicutes Gut microbe in GI diseases EI
52 Bulleidia s__ 0.1 Firmicutes Fecal-associated and mucosalassociated microbiota in irritable bowel syndrome patients EJ
53 Coprobacillus s__ 0.1 Firmicutes Alters Gut Microbiota in Psoriatic Arthritis EL
54 Leptotrichia s__ 0.5 Fusobacteria Causes gut mucosal inflammation in Rheumatoid arthritis patients EO
55 g__ s__ 3.6 Proteobacteria Intestinal microbe in children with severe and complicated acute viral gastroenteritis EV
56 g__ s__ 0.5 Proteobacteria Causes chronic inflammation in IBD FB
57 g__ s__ 0.1 Proteobacteria Microbial factor associated with postoperative Crohn's disease FD
58 g__ s__ 1.5 Proteobacteria Involved in host-microbial cross talk in IBD FG
59 Sutterella s__ 0.1 Proteobacteria Gut microbe in experimental colitis FH
60 Lautropia s__ 0.2 Proteobacteria Causes fecal microbial dysbiosis in IBD FJ
61 g__ s__ 0.5 Proteobacteria Fecal and mucosa associated microbe in IBD FK
62 Citrobacter s__ 0.3 Proteobacteria Gut microbe in newly diagnosed with treatment-naïve Crohn's disease patients FY
63 Halomonas s__ 0.8 Proteobacteria Intestinal microflora in chronic kidney disease GB
64 g__ s__ 0.3 Proteobacteria Bacteria in human Ulcerative Colitis patients GH
65 Other Other 0.2 Actinobacteria Alters fecal microbiota in pediatric IBD patients GO
66 Eggerthella Other 0.1 Actinobacteria Causes bacteremia in Crohn's disease patient GQ
67 Other Other 4.0 Firmicutes Gut microbe in experimental colitis GT
68 Other Other 4.2 Firmicutes Fecal and mucosa associated microbe in IBD GW
69 Weissella Other 1.2 Firmicutes Gut microbe in IBD patients GX
70 Other Other 2.5 Proteobacteria Causes microbial dysbiosis in pediatric Crohn's disease HD
71 Other Other 1.4 Proteobacteria Fecal and mucosa associated microbe in IBD HL
DISEASED COLON (CROHN'S COLITIS)
1 Ochrobactrum s__ 0.1 Proteobacteria Causes early bacterial dependent induction of inducible nitric oxide synthase (iNOS) in epithelial cells in experimental colitis EU
2 Sphingomonas s__ 0.1 Proteobacteria Tissue associated intestinal microflora FF
3 Burkholderia s__ 1.6 Proteobacteria Causes dysfunction of GALT and gut flora in IBD FI
4 Acinetobacter rhizosphaerae 1.8 Proteobacteria Identified gut microbe in IBD K
5 Acinetobacter lwoffii 0.5 Proteobacteria Gut bacteria in multiple sclerosis patients W
6 Acinetobacter Other 1.6 Proteobacteria Tissue associated intestinal microflora in colitis patients HQ
7 Stenotrophomonas geniculata 0.3 Proteobacteria Identified gut microbe in IBD AG
8 Enterococcus s__ 0.1 Firmicutes Induces experimental IBD CV
9 Staphylococcus sciuri 0.1 Firmicutes Develops intestinal inflammation in acute and chronic colitis I
10 Staphylococcus aureus 0.6 Firmicutes Causes Crohn's disease AU
11 Lactobacillus zeae 1.9 Firmicutes Maintains remission of ulcerative colitis A
12 Lactobacillus s__ 0.4 Firmicutes Maintains remission of ulcerative colitis CW
13 Lactococcus s__ 0.7 Firmicutes Used in the treatment of Crohn's disease CX
14 Pseudomonas alcaligenes 1.8 Proteobacteria Identified in the gut microbiota of IBD AX
15 Pseudomonas s__ 0.1 Proteobacteria Infection in Children with Early-onset Crohn's Disease GG
16 Pseudomonas Other 0.2 Proteobacteria Gut microbe in children with early onset Crohn's disease HR
17 Bacillus thermoamylovorans 0.2 Firmicutes A probiotic- normal flora of the gut E
18 Bacillus s__ 2.6 Firmicutes Increases cytokine levels in IBD CL
19 Bacteroides eggerthii 0.1 Bacteroidetes Enhances colitis in mice AJ
20 Bacteroides Other 0.4 Bacteroidetes Commensal bacteria that induces colitis GR
21 Microbacterium maritypicum 0.1 Actinobacteria Fecal microbiome in Obesity V
22 Eggerthella lenta 4.5 Actinobacteria Causes bacteremia in Crohn's disease patient AA
23 Brevundimonas diminuta 0.2 Proteobacteria Identified in the adult fecal microbiota of allergy patients AO
24 Propionibacterium acnes 1.2 Actinobacteria Intestinal microbe in Liver disease BA
25 Methanobrevibacter s__ 0.8 Euryarchaeota Identified in the gut of IBD patients BB
26 g__ s__ 0.7 Acidobacteria Identified in the gut microbiome of Type 2 Diabetes patients BD
27 g__ s__ 0.2 Actinobacteria Identified in gut microbiota in IBD BE
28 g__ s__ 0.5 Actinobacteria Identified in gut microbiota in IBD BF
29 Microbacterium s__ 0.1 Actinobacteria Identified in the duodenum of children with ulcerative colitis BK
30 Bifidobacterium s__ 0.2 Actinobacteria Identified in gut microbiota of IBD patients BO
31 g__ s__ 0.3 Actinobacteria Identified in fecal microbiota of pediatric IBD patients BP
32 Atopobium s__ 0.2 Actinobacteria Altered intestinal microbiota in Crohn's disease BR
33 Slackia s__ 1.3 Actinobacteria Alters human gut microbiome in Multiple Sclerosis BS
34 g__ s__ 0.1 Bacteroidetes Identified in gut microbiome of IBD patients CA
35 g__ s__ 0.3 Bacteroidetes Human gut microbe in Obesity and IBD CC
36 g__ s__ 0.7 Firmicutes Causes microbiota dysbiosis in IBD CO
37 g__ s__ 0.2 Firmicutes Gut microbe in IBD DA
38 g__ s__ 0.9 Firmicutes A microbial signature of Crohn's disease DB
39 Clostridium s__ 0.6 Firmicutes Causes infection of the gut in IBD DE
40 Lachnospira s__ 0.6 Firmicutes Gut bacteria in Crohn's disease patients DK
41 Moryella s__ 0.1 Firmicutes Microbe in Inflammatory Pouch Complications DL
42 g__ s__ 0.1 Firmicutes gut microbe in IBD DP
43 g__ s__ 0.6 Firmicutes A microbial signature of Crohn's disease DQ
44 Oscillospira s__ 0.2 Firmicutes Gut microbe in IBD patients DU
45 Ruminococcus s__ 0.9 Firmicutes Dominant in gut microbiome of IBD patients DV
46 g__ s__ 0.2 Firmicutes Gut microbe underlying the onset of IBD DW
47 Acidaminococcus s__ 1.0 Firmicutes Gut microbe in IBD DX
48 Phascolarctobacterium s__ 0.6 Firmicutes Causes dysfunction of the intestinal microbiome in IBD DZ
49 Schwartzia s__ 0.2 Firmicutes Causes fecal microbial dysbiosis in IBD EA
50 g__ s__ 0.1 Firmicutes A microbial signature of Crohn's disease EC
51 Anaerococcus s__ 0.3 Firmicutes Microbe in Inflammatory Pouch Complications EE
52 Finegoldia s__ 0.4 Firmicutes Intestinal microbe in colorectal cancer EF
53 g__ s__ 0.5 Firmicutes Gut microbe in GI diseases EI
54 Bulleidia s__ 0.2 Firmicutes Fecal-associated and mucosalassociated microbiota in irritable bowel syndrome patients EJ
55 Coprobacillus s__ 0.3 Firmicutes Alters Gut Microbiota in Psoriatic Arthritis EL
56 Leptotrichia s__ 0.5 Fusobacteria Causes gut mucosal inflammation in Rheumatoid arthritis patients EO
57 g__ s__ 4.1 Proteobacteria Intestinal microbe in children with severe and complicated acute viral gastroenteritis EV
58 g__ s__ 0.2 Proteobacteria Microbial factor associated with postoperative Crohn's disease FD
59 g__ s__ 1.2 Proteobacteria Involved in host-microbial cross talk in IBD FG
60 Sutterella s__ 0.1 Proteobacteria Gut microbe in experimental colitis FH
61 Lautropia s__ 0.1 Proteobacteria Causes fecal microbial dysbiosis in IBD FJ
62 g__ s__ 0.4 Proteobacteria Fecal and mucosa associated microbe in IBD FK
63 g__ s__ 0.1 Proteobacteria Bacteria in Mucosal and Submucosal Intestinal Tissues in Advanced Crohn's Disease FN
64 Ralstonia s__ 0.1 Proteobacteria Microbiota in the Mucosa of Patients With Ulcerative Colitis FP
65 Halomonas s__ 0.5 Proteobacteria Intestinal microflora in chronic kidney disease GB
66 Haemophilus s__ 0.7 Proteobacteria Treatment naïve microbiome in new onset Crohn's disease GD
67 g__ s__ 0.1 Proteobacteria Microbe in colon tissue from IBD subjects GE
68 Other Other 1.1 Actinobacteria Alters fecal microbiota in pediatric IBD patients GO
69 Eggerthella Other 0.1 Actinobacteria Causes bacteremia in Crohn's disease patient GQ
70 Other Other 1.7 Firmicutes Gut microbe in experimental colitis GT
71 Other Other 2.2 Firmicutes Fecal and mucosa associated microbe in IBD GW
72 Weissella Other 2.2 Firmicutes Gut microbe in IBD patients GX
73 Other Other 0.1 Proteobacteria Causes microbial dysbiosis in pediatric Crohn's disease HD
74 Methylobacterium Other 0.1 Proteobacteria Causes gut microbial dysbiosis in pediatric Crohn's disease patients HG
75 Other Other 0.2 Proteobacteria Fecal and mucosa associated microbe in IBD HK
76 Other Other 0.6 Proteobacteria Fecal and mucosa associated microbe in IBD HL

Specific Information of functions was adapted from NCBI Genome Database (https://www.ncbi.nlm.nih.gov/genome/).

The bacterial species that could not be identified at the genus level are mentioned as g___ and the bacterial species that could not be identified at the species level are mentioned as s___.

Table 2.

Functions and proportions of specific beneficial Gut bacteria colonized in full thickness colon specimens.

Sl. No. Bacteria genus Bacteria species Proportion (%) Bacteria phylum Function in IBD NCBI genome database link
ADJACENT HEALTHY COLON
1 Shuttleworthia satelles 0.2 Firmicutes Identified in the human ileum J
2 Bifidobacterium longum 0.1 Actinobacteria Attenuates acute murine experimental model of IBD Y
3 Rhizobium leguminosarum 0.1 Proteobacteria Identified commensal gut microbe AB
4 Lysinibacillus boronitolerans 12.1 Firmicutes Identified commensal gut microbe AT
5 Alloiococcus s__ 1.7 Firmicutes Identified commensal gut microbe CT
6 Christensenella s__ 2.2 Firmicutes Identified gut microbe DC
7 Blautia s__ 0.3 Firmicutes Butyrate-producing bacterial species in Gut DH
8 Coprococcus s__ 0.1 Firmicutes Butyrate-producing bacterial species in Gut DI
9 g__ s__ 0.7 Gemmatimonadetes Identified commensal gut microbe EP
10 g__ s__ 0.7 Lentisphaerae Normal gut microbe EQ
11 g__ s__ 0.4 Proteobacteria Identified commensal gut microbe FC
12 Comamonas s__ 1.0 Proteobacteria Identified commensal gut microbe FL
13 Desulfovibrio s__ 0.3 Proteobacteria Sulfate reducing bacteria in IBD FV
14 Paracoccus Other 0.1 Proteobacteria Identified commensal gut microbe HH
15 Other Other 0.2 Proteobacteria Mucosal and fecal microbe HP
DISEASED COLON (ULCERATIVE COLITIS)
1 Lysinibacillus boronitolerans 8.2 Firmicutes Identified commensal gut microbe AT
2 Varibaculum s__ 0.2 Actinobacteria Identified in the gut of a premature infant BH
3 Alloiococcus s__ 3.1 Firmicutes Identified commensal gut microbe CT
4 Christensenella s__ 0.6 Firmicutes Identified gut microbe DC
5 Blautia s__ 0.3 Firmicutes Butyrate-producing bacterial species in Gut DH
6 Coprococcus s__ 0.2 Firmicutes Butyrate-producing bacterial species in Gut DI
7 g__ s__ 0.3 Gemmatimonadetes Identified commensal gut microbe EP
8 g__ s__ 0.3 Proteobacteria Identified commensal gut microbe FC
9 Comamonas s__ 2.7 Proteobacteria Identified commensal gut microbe FL
10 Desulfovibrio s__ 0.1 Proteobacteria Sulfate reducing bacteria in IBD FV
11 Morganella s__ 0.1 Proteobacteria Sulfate reducing bacteria in IBD FZ
12 g__ s__ 0.6 TM7 Identified commensal gut microbe
13 Other Other 0.1 Actinobacteria Commensal gut bacteria in IBD GN
14 Other Other 0.5 Proteobacteria Adult fecal microbe HO
DISEASED COLON (CROHN'S COLITIS)
1 Akkermansia muciniphila 0.1 Verrucomicrobia Adheres to enterocytes and strengthens the integrity of the epithelial cell layer S
2 Bifidobacterium longum 0.4 Actinobacteria Attenuates acute murine experimental model of IBD Y
3 Rhizobium leguminosarum 0.2 Proteobacteria Identified commensal gut microbe AB
4 Anoxybacillus kestanbolensis 0.3 Firmicutes Identified commensal gut microbe AD
5 Lysinibacillus boronitolerans 11.5 Firmicutes Identified commensal gut microbe AT
6 g__ s__ 0.1 Acidobacteria Identified in human gut microbiota BC
7 Varibaculum s__ 0.1 Actinobacteria Identified in the gut of a premature infant BH
8 SHD-231 s__ 0.1 Chloroflexi Identified in the fecal microbiome of Gout patients CH
9 g__ s__ 0.1 Cyanobacteria Identified in human gut microbiota CJ
10 Alloiococcus s__ 7.1 Firmicutes Identified commensal gut microbe CT
11 Christensenella s__ 0.1 Firmicutes Identified gut microbe DC
12 g__ s__ 0.1 Firmicutes Commensal gut bacteria in IBD DG
13 Blautia s__ 0.1 Firmicutes Butyrate-producing bacterial species in Gut DH
14 Coprococcus s__ 0.1 Firmicutes Butyrate-producing bacterial species in Gut DI
15 g__ s__ 0.3 Gemmatimonadetes Identified commensal gut microbe EP
16 g__ s__ 0.3 Lentisphaerae Normal gut microbe EQ
17 Comamonas s__ 2.4 Proteobacteria Identified commensal gut microbe FL
18 g__ s__ 0.1 Proteobacteria Identified commensal gut microbe FT
19 Desulfovibrio s__ 0.2 Proteobacteria Sulfate reducing bacteria in IBD FV
20 g__ s__ 0.3 TM7 Identified commensal gut microbe
21 Other Other 0.2 Firmicutes Commensal gut bacteria in IBD HA
22 Paracoccus Other 0.7 Proteobacteria Identified commensal gut microbe HH
23 Other Other 0.1 Proteobacteria Identified commensal gut microbe HN
24 Other Other 0.7 Proteobacteria Adult fecal microbe HO

Specific Information of functions was adapted from NCBI Genome Database (https://www.ncbi.nlm.nih.gov/genome/).

The bacterial species that could not be identified at the genus level are mentioned as g___ and the bacterial species that could not be identified at the species level are mentioned as s___.

Statistical Analysis and Evaluation

Statistical analysis was performed between the healthy and diseased groups and based on race classification (n = 13 CC, n = 13 UC, n = 13 non-disease healthy patients, n = 30 CA and n = 9 AA). A non-parametric Mann-Whitney U Test p-value < 0.05 of bacterial 16S rRNA OTUs between the groups was considered statistically significant. IBM SPSS software package version 23 (IBM Analytics, USA) was used to conduct statistical analysis.

Results

Relative Abundance Analysis

QIIME analysis showed about two hundred twenty-eight bacterial species in entire 39 specimens (Tables 15). However, non-ambiguous annotation at the species name resulted in fifty-three bacterial identifications. The dominant phyla across all samples (both diseased and healthy specimens) were Bacteroidetes (46.92%), followed by Firmicutes (27.8%), and Proteobacteria (24.5%). Most importantly, our results indicate that putative oral pathogens (belonging to mostly Phylum Firmicutes) dominated the microbiome of diseased specimens (Figure 1). Adjacent healthy specimens show an increased abundance of Phylum Bacteroidetes (~ 57%, containing mostly symbiotic and/or beneficial bacteria) population, which is altered in disease categories (Figure 2).

Figure 2.

Figure 2

Perturbation of the full thickness colon microbiome in Colitis specimens as compared to adjacent healthy specimens. Specimens are categorized into adjacent healthy colon (n = 13), Ulcerative colitis (UC, n = 13) and Crohn's colitis (CC, n = 13). Data represented are the mean of relative abundances of each phylum identified in specimens belonging to each group while error bars indicate standard error. Diseased specimens demonstrate a balance between the Phyla Firmicutes and Bacteroidetes. Conversely, healthy colon specimens demonstrate a significantly higher proportion of Phyla Bacteroidetes. *p < 0.05 by Mann-Whitney U Test (n = 13 under each group).

Differential Expression of Microbiomes in the Colon of CA and AA Patients

Figure 3 show racial differences of various bacterial phyla in adjacent healthy, UC and CC full thickness colon specimens. The tissue specimens from Caucasians represented a significantly higher proportion (p < 0.05) of the oral pathogen, Fusobacterium, and gut bacteria, Parabacteroides (Bacteroidetes). CA specimens also showed significantly higher levels (p < 0.05) of Phyla Proteobacteria including Citrobacter, Hemophilus, Acinetobacter, Pseudomonas, and Stenotrophomonas as compared to AA. Whereas, the AA specimens were observed to have a significantly higher proportion (p < 0.05) of Prevotella (Bacteroidetes) and Clostridia (Firmicutes) (Figure 3; Table 4).

Figure 3.

Figure 3

Summary of major bacterial taxa showing the relative abundance of oral and gut bacteria at the Phylum level in the colitis and adjacent healthy specimen groups under each race. Data represented are the mean of relative abundances of each Phyla detected in samples belonging to each group. The dominant phyla across all samples (both diseased and healthy specimens) were Bacteroidetes, followed by Firmicutes and Proteobacteria. Other major phyla observed among these specimens also include Actinobacteria, Fusobacteria, and Synergistetes. The Phylum Proteobacteria did not show any significant difference between healthy colon specimens and diseased colon specimens. A larger proportion of unassigned bacteria (0.3%) was identified in AA Crohn's Colitis patients compared to other groups.

Table 4.

Functions and Proportions of bacterial species identified in the full thickness human colon specimens of Caucasians and African Americans.

Sl. No. Bacteria genus Bacteria species Proportion (%) Bacteria phylum Function in IBD NCBI genome database link
CAUCASIAN AMERICANS
1 Lactobacillus zeae 6.8 Firmicutes Maintains remission of ulcerative colitis A
2 Bacillus thermoamylovorans 0.1 Firmicutes A probiotic- normal flora of the gut E
3 Prevotella tannerae 0.1 Bacteroidetes Prevalent in colitis F
4 Collinsella stercoris 0.0 Actinobacteria Used for treatment of IBD G
5 Prevotella stercorea 1.4 Bacteroidetes Alters mucosal microbiota in the colon of patients with IBD H
6 Staphylococcus sciuri 0.1 Firmicutes Develops intestinal inflammation in acute and chronic colitis I
7 Shuttleworthia satelles 0.0 Firmicutes Identified in the human ileum J
8 Acinetobacter rhizosphaerae 1.1 Proteobacteria Identified gut microbe in IBD K
9 Blautia producta 0.1 Firmicutes Gut microbe in Obesity and IBD N
10 Akkermansia muciniphila 0.1 Verrucomicrobia Adheres to enterocytes and strengthens the integrity of the epithelial cell layer S
11 Prevotella melaninogenica 0.2 Bacteroidetes Gut microbiome biomarker in ankylosing spondylitis U
12 Acinetobacter lwoffii 0.2 Proteobacteria Gut bacteria in multiple sclerosis patients W
13 Bifidobacterium longum 0.2 Actinobacteria Attenuates acute murine experimental model of IBD Y
14 Eggerthella lenta 4.3 Actinobacteria Causes bacteremia in Crohn's disease patient AA
15 Rhizobium leguminosarum 0.1 Proteobacteria Identified gut microbe in IBD patients AB
16 Anoxybacillus kestanbolensis 0.1 Firmicutes Identified gut microbe in IBD patients AD
17 Stenotrophomonas geniculata 0.1 Proteobacteria Identified gut microbe in IBD patients AG
18 Corynebacterium durum 0.1 Actinobacteria Identified gut microbe in IBD patients AK
19 Eubacterium dolichum 0.8 Firmicutes Causes dysbiosis of the intestinal microbiota AL
20 Brevundimonas diminuta 0.1 Proteobacteria Identified in the adult fecal microbiota of allergy patients AO
21 Lysinibacillus boronitolerans 12.3 Firmicutes Identified gut microbe in IBD patients AT
22 Staphylococcus aureus 0.6 Firmicutes Causes Crohn's disease AU
23 Peptostreptococcus anaerobius 4.8 Firmicutes Causes dysbiosis in IBD AW
24 Pseudomonas alcaligenes 1.0 Proteobacteria Identified in the gut microbiota of IBD AX
25 Propionibacterium acnes 3.9 Actinobacteria Intestinal microbe in Liver disease BA
26 Methanobrevibacter s__ 0.6 Euryarchaeota Identified in the gut of IBD BB
27 g__ s__ 0.8 Acidobacteria Identified in the gut microbiome of Type 2 Diabetes patients BD
28 g__ s__ 0.9 Actinobacteria Identified in gut microbiota in IBD BF
29 Varibaculum s__ 0.1 Actinobacteria Identified in the gut of a premature infant BH
30 Corynebacterium s__ 0.7 Actinobacteria Causes experimental colitis BI
31 Microbacterium s__ 0.1 Actinobacteria Identified in the duodenum of children with ulcerative colitis BK
32 Bifidobacterium s__ 0.1 Actinobacteria identified in gut microbiota of IBD patients BO
33 g__ s__ 0.2 Actinobacteria Identified in fecal microbiota of pediatric IBD patients BP
34 Adlercreutzia s__ 0.1 Actinobacteria Causes dysbiosis in IBD patients BQ
35 Atopobium s__ 0.1 Actinobacteria altered intestinal microbiota in Crohn's disease BR
36 Slackia s__ 0.7 Actinobacteria Alters human gut microbiome in Multiple Sclerosis BS
37 Prevotella s__ 0.1 Bacteroidetes A microbial signature of Crohn's disease BZ
38 g__ s__ 0.4 Bacteroidetes Identified in gut microbiome of IBD patients CA
39 g__ s__ 0.2 Bacteroidetes Characterized in intestinal biopsies in IBD patients CB
40 g__ s__ 0.2 Bacteroidetes Human gut microbe in Obesity and IBD CC
41 Cloacibacterium s__ 0.7 Bacteroidetes Identified in the rectum of human colorectal adenoma patients CG
42 SHD-231 s__ 0.1 Chloroflexi Identified in the fecal microbiome of Gout patients CH
43 g__ s__ 0.1 Cyanobacteria Identified in the gut microbiome of IBD patients CI
44 Calothrix s__ 0.1 Cyanobacteria Identified gut microbe in IBD patients CK
45 Bacillus s__ 0.5 Firmicutes Increases cytokine levels in IBD CL
46 g__ s__ 0.6 Firmicutes Causes microbiota dysbiosis in IBD CO
47 Gemella s__ 0.1 Firmicutes Microbiome in New-Onset Crohn's Disease CP
48 Abiotrophia s__ 0.1 Firmicutes Causes fecal microbial dysbiosis in IBD CS
49 Alloiococcus s__ 3.4 Firmicutes Identified gut microbe in IBD patients CT
50 Enterococcus s__ 0.4 Firmicutes Induces experimental IBD CV
51 Lactobacillus s__ 0.5 Firmicutes Maintains remission of ulcerative colitis CW
52 Lactococcus s__ 0.7 Firmicutes Used in the treatment of Crohn's disease CX
53 g__ s__ 0.1 Firmicutes Gut microbe in IBD DA
54 g__ s__ 1.1 Firmicutes A microbial signature of Crohn's disease DB
55 Christensenella s__ 1.2 Firmicutes Identified gut microbe DC
56 Clostridium s__ 0.9 Firmicutes causes infection of the gut in IBD DE
57 Pseudoramibacter_Eubacterium s__ 1.8 Firmicutes Metabolizes Linoleic acid in the Gut DF
58 g__ s__ 0.1 Firmicutes Commensal gut bacteria in IBD DG
59 Blautia s__ 0.3 Firmicutes Butyrate-producing bacterial species in Gut DH
60 Coprococcus s__ 0.2 Firmicutes Butyrate-producing bacterial species in Gut DI
61 Dorea s__ 0.1 Firmicutes Causes dysfunction of the intestinal microbiome in IBD DJ
62 Lachnospira s__ 0.3 Firmicutes Gut bacteria in Crohn's disease patients DK
63 g__ s__ 0.1 Firmicutes Gut microbe in IBD DP
64 g__ s__ 0.6 Firmicutes A microbial signature of Crohn's disease DQ
65 Peptostreptococcus s__ 0.3 Firmicutes Causes gut microbiota dysbiosis in IBD DR
66 Anaerotruncus s__ 0.1 Firmicutes Tissue associated intestinal microflora DT
67 Oscillospira s__ 0.2 Firmicutes Gut microbe in IBD patients DU
68 Ruminococcus s__ 0.4 Firmicutes Dominant in gut microbiome of IBD patients DV
69 g__ s__ 0.3 Firmicutes Gut microbe underlying the onset of IBD DW
70 Acidaminococcus s__ 1.2 Firmicutes Gut microbe in IBD DX
71 Phascolarctobacterium s__ 1.9 Firmicutes Causes dysfunction of the intestinal microbiome in IBD DZ
72 Schwartzia s__ 0.5 Firmicutes Causes fecal microbial dysbiosis in IBD EA
73 Selenomonas s__ 0.2 Firmicutes Causes dysbiosis in colorectal cancer EB
74 g__ s__ 0.1 Firmicutes A microbial signature of Crohn's disease EC
75 Anaerococcus s__ 0.7 Firmicutes Microbe in Inflammatory Pouch Complications EE
76 Finegoldia s__ 0.3 Firmicutes Intestinal microbe in colorectal cancer EF
77 g__ s__ 0.4 Firmicutes Gut microbe in GI diseases EI
78 Bulleidia s__ 0.1 Firmicutes Fecal-associated and mucosalassociated microbiota in irritable bowel syndrome patients EJ
79 Coprobacillus s__ 0.3 Firmicutes Alters Gut Microbiota in Psoriatic Arthritis EL
80 Fusobacterium s__ 0.8 Fusobacteria Identified from colonic biopsies of IBD patients EN
81 Leptotrichia s__ 0.2 Fusobacteria Causes gut mucosal inflammation in Rheumatoid arthritis patients EO
82 g__ s__ 0.3 Gemmatimonadetes Identified gut microbe in IBD patients EP
83 g__ s__ 0.4 Lentisphaerae Normal gut microbe EQ
84 Ochrobactrum s__ 0.1 Proteobacteria Causes early bacterial dependent induction of inducible nitric oxide synthase (iNOS) in epithelial cells in experimental colitis EU
85 g__ s__ 4.7 Proteobacteria Intestinal microbe in children with severe and complicated acute viral gastroenteritis EV
86 g__ s__ 0.2 Proteobacteria Causes chronic inflammation in IBD FB
87 g__ s__ 0.3 Proteobacteria Identified gut microbe in IBD patients FC
88 g__ s__ 0.1 Proteobacteria Microbial factor associated with postoperative Crohn's disease FD
89 Sphingomonas s__ 0.3 Proteobacteria Tissue associated intestinal microflora FF
90 g__ s__ 1.7 Proteobacteria Involved in host-microbial cross talk in IBD FG
91 Sutterella s__ 0.1 Proteobacteria gut microbe in experimental colitis FH
92 Burkholderia s__ 1.2 Proteobacteria Causes dysfunction of GALT and gut flora in IBD FI
93 Lautropia s__ 0.2 Proteobacteria Causes fecal microbial dysbiosis in IBD FJ
94 g__ s__ 0.4 Proteobacteria Fecal and mucosa associated microbe in IBD FK
95 Comamonas s__ 2.5 Proteobacteria Identified gut microbe in IBD patients FL
96 Delftia s__ 0.1 Proteobacteria Fecal and mucosa associated microbe in IBD FM
97 Desulfovibrio s__ 0.2 Proteobacteria Sulfate reducing bacteria in IBD FV
98 Citrobacter s__ 0.2 Proteobacteria Gut microbe in newly diagnosed with treatment-naïve Crohn's disease patients FY
99 Halomonas s__ 0.9 Proteobacteria Intestinal microflora in chronic kidney disease GB
100 Aggregatibacter s__ 0.6 Proteobacteria Causes fungal microbiota dysbiosis in IBD GC
101 Haemophilus s__ 0.3 Proteobacteria Treatment naïve microbiome in new onset Crohn's disease GD
102 Pseudomonas s__ 0.8 Proteobacteria Infection in Children with Early-onset Crohn's Disease GG
103 g__ s__ 0.2 Proteobacteria Bacteria in human Ulcerative Colitis patients GH
104 g__ s__ 0.1 TM7 No role in IBD
105 Other Other 0.5 Actinobacteria Alters fecal microbiota in pediatric IBD patients GO
106 Eggerthella Other 0.1 Actinobacteria Causes bacteremia in Crohn's disease patient GQ
107 Bacteroides Other 0.1 Bacteroidetes Commensal bacteria that induces colitis GR
108 Prevotella Other 0.7 Bacteroidetes A microbial signature of Crohn's disease GS
109 Other Other 3.2 Firmicutes Gut microbe in experimental colitis GT
110 Other Other 7.5 Firmicutes Fecal and mucosa associated microbe in IBD GW
111 Weissella Other 1.5 Firmicutes Gut microbe in IBD patients GX
112 Other Other 0.1 Firmicutes Commensal gut bacteria in IBD HA
113 Other Other 1.1 Proteobacteria Causes microbial dysbiosis in pediatric Crohn's disease HD
114 Paracoccus Other 0.3 Proteobacteria Identified gut microbe in IBD patients HH
115 Other Other 0.1 Proteobacteria Fecal and mucosa associated microbe in IBD HK
116 Other Other 0.7 Proteobacteria Fecal and mucosa associated microbe in IBD HL
117 Other Other 0.1 Proteobacteria Identified gut microbe in IBD patients HN
118 Other Other 0.5 Proteobacteria Adult fecal microbe HO
AFRICAN AMERICANS
1 Lactobacillus zeae 1.1 Firmicutes Maintains remission of ulcerative colitis A
2 Prevotella stercorea 4.6 Bacteroidetes Alters mucosal microbiota in the colon of patients with IBD H
3 Shuttleworthia satelles 0.4 Firmicutes Identified in the human ileum J
4 Acinetobacter rhizosphaerae 0.2 Proteobacteria Identified gut microbe in IBD patients K
5 Microbacterium maritypicum 0.2 Actinobacteria Fecal microbiome in Obesity V
6 Acinetobacter lwoffii 0.5 Proteobacteria Gut bacteria in multiple sclerosis patients W
7 Eggerthella lenta 0.7 Actinobacteria Causes bacteremia in Crohn's disease patient. AA
8 Stenotrophomonas geniculata 2.0 Proteobacteria Identified gut microbe in IBD patients AG
9 Corynebacterium durum 0.1 Actinobacteria Identified gut microbe in IBD patients AK
10 Eubacterium dolichum 0.5 Firmicutes Causes dysbiosis of the intestinal microbiota AL
11 Brevundimonas diminuta 0.1 Proteobacteria Identified in the adult fecal microbiota of allergy patients AO
12 Lysinibacillus boronitolerans 5.0 Firmicutes Identified gut microbe in IBD patients AT
13 Staphylococcus aureus 0.2 Firmicutes Causes Crohn's disease AU
14 Peptostreptococcus anaerobius 24.9 Firmicutes Causes dysbiosis in IBD AW
15 Pseudomonas alcaligenes 1.1 Proteobacteria Identified in the gut microbiota of IBD AX
16 Propionibacterium acnes 0.6 Actinobacteria Intestinal microbe in Liver disease BA
17 Methanobrevibacter s__ 0.4 Euryarchaeota Identified in the gut of IBD BB
18 g__ s__ 0.2 Acidobacteria Identified in human gut microbiota BC
19 g__ s__ 4.3 Acidobacteria Identified in the gut microbiome of Type 2 Diabetes patients BD
20 g__ s__ 0.3 Actinobacteria Identified in gut microbiota in IBD BE
21 Varibaculum s__ 0.6 Actinobacteria Identified in the gut of a premature infant BH
22 Corynebacterium s__ 0.5 Actinobacteria Causes experimental colitis BI
23 Arthrobacter s__ 0.2 Actinobacteria Fecal microflora in chronic IBD patients BL
24 Slackia s__ 0.2 Actinobacteria Alters human gut microbiome in Multiple Sclerosis BS
25 Chryseobacterium s__ 0.3 Bacteroidetes Fecal and mucosa associated microbe in IBD CF
26 Cloacibacterium s__ 0.2 Bacteroidetes Identified in the rectum of human colorectal adenoma patients CG
27 g__ s__ 0.2 Cyanobacteria Identified in human gut microbiota CJ
28 Bacillus s__ 2.7 Firmicutes Increases cytokine levels in IBD CL
29 Alloiococcus s__ 6.0 Firmicutes Identified gut microbe in IBD patients CT
30 Lactobacillus s__ 0.2 Firmicutes Maintains remission of ulcerative colitis CW
31 Lactococcus s__ 0.3 Firmicutes Used in the treatment of Crohn's disease CX
32 g__ s__ 0.1 Firmicutes Gut microbe in IBD DA
33 g__ s__ 1.3 Firmicutes A microbial signature of Crohn's disease DB
34 Christensenella s__ 0.2 Firmicutes Identified gut microbe DC
35 Clostridium s__ 0.4 Firmicutes causes infection of the gut in IBD DE
36 Pseudoramibacter_Eubacterium s__ 0.9 Firmicutes Metabolizes Linoleic acid in the Gut DF
37 Lachnospira s__ 0.3 Firmicutes Gut bacteria in Crohn's disease patients DK
38 g__ s__ 0.3 Firmicutes A microbial signature of Crohn's disease DQ
39 Peptostreptococcus s__ 0.4 Firmicutes Causes gut microbiota dysbiosis in IBD DR
40 Oscillospira s__ 0.2 Firmicutes Gut microbe in IBD patients DU
41 Ruminococcus s__ 2.2 Firmicutes Dominant in gut microbiome of IBD patients DV
42 g__ s__ 0.4 Firmicutes Gut microbe underlying the onset of IBD DW
43 Acidaminococcus s__ 1.0 Firmicutes Gut microbe in IBD DX
44 Phascolarctobacterium s__ 0.5 Firmicutes Causes dysfunction of the intestinal microbiome in IBD DZ
45 Schwartzia s__ 0.1 Firmicutes Causes fecal microbial dysbiosis in IBD EA
46 Selenomonas s__ 0.5 Firmicutes Causes dysbiosis in colorectal cancer EB
47 Anaerococcus s__ 0.5 Firmicutes Microbe in Inflammatory Pouch Complications EE
48 Finegoldia s__ 0.4 Firmicutes Intestinal microbe in colorectal cancer EF
49 g__ s__ 0.8 Firmicutes Gut microbe in GI diseases EI
50 Bulleidia s__ 0.1 Firmicutes Fecal-associated and mucosalassociated microbiota in irritable bowel syndrome patients EJ
51 Fusobacterium s__ 8.4 Fusobacteria Identified from colonic biopsies of IBD patients EN
52 Leptotrichia s__ 1.7 Fusobacteria Causes gut mucosal inflammation in Rheumatoid arthritis patients EO
53 g__ s__ 0.7 Gemmatimonadetes Identified gut microbe in IBD patients EP
54 Ochrobactrum s__ 0.1 Proteobacteria Causes early bacterial dependent induction of inducible nitric oxide synthase (iNOS) in epithelial cells in experimental colitis EU
55 g__ s__ 1.5 Proteobacteria Intestinal microbe in children with severe and complicated acute viral gastroenteritis EV
56 g__ s__ 0.1 Proteobacteria Involved in host-microbial cross talk in IBD FG
57 Sutterella s__ 0.2 Proteobacteria Gut microbe in experimental colitis FH
58 Burkholderia s__ 0.4 Proteobacteria Causes dysfunction of GALT and gut flora in IBD FI
59 Lautropia s__ 0.2 Proteobacteria Causes fecal microbial dysbiosis in IBD FJ
60 Comamonas s__ 0.4 Proteobacteria Identified gut microbe in IBD patients FL
61 Ralstonia s__ 0.2 Proteobacteria Microbiota in the Mucosa of Patients With Ulcerative Colitis FP
62 Bilophila s__ 0.1 Proteobacteria Causes irritable bowel syndrome FU
63 Desulfovibrio s__ 0.1 Proteobacteria Sulfate reducing bacteria in IBD FV
64 Halomonas s__ 0.7 Proteobacteria Intestinal microflora in chronic kidney disease GB
65 g__ s__ 0.1 Proteobacteria Microbe in colon tissue from IBD subjects GE
66 Acinetobacter s__ 0.7 Proteobacteria Tissue associated intestinal microflora GF
67 Pseudomonas s__ 0.1 Proteobacteria Infection in Children with Early-onset Crohn's Disease GG
68 g__ s__ 0.8 TM7 No role in IBD
69 Other Other 0.3 Actinobacteria Alters fecal microbiota in pediatric IBD patients GO
70 Eggerthella Other 0.1 Actinobacteria Causes bacteremia in Crohn's disease patient GQ
71 Bacteroides Other 0.7 Bacteroidetes Commensal bacteria that induces colitis GR
72 Prevotella Other 3.2 Bacteroidetes A microbial signature of Crohn's disease GS
73 Other Other 2.8 Firmicutes Gut microbe in experimental colitis GT
74 Paenibacillus Other 0.1 Firmicutes Gut microbe in a healthy infant GU
75 Other Other 2.2 Firmicutes Fecal and mucosa associated microbe in IBD GW
76 Paracoccus Other 0.1 Proteobacteria Identified gut microbe in IBD patients HH
77 Other Other 0.6 Proteobacteria Fecal and mucosa associated microbe in IBD HL
78 Other Other 0.1 Proteobacteria Adult fecal microbe HO
79 Other Other 0.4 Proteobacteria Mucosal and fecal microbe HP
80 Acinetobacter Other 2.2 Proteobacteria Tissue associated intestinal microflora in colitis patients HQ
81 Pseudomonas Other 0.2 Proteobacteria Gut microbe in children with early onset Crohn's disease HR

Specific Information of functions was adapted from NCBI Genome Database (https://www.ncbi.nlm.nih.gov/genome/).

The bacterial species that could not be identified at the genus level are mentioned as g___ and the bacterial species that could not be identified at the species level are mentioned as s___.

As depicted in Figure 3, the adjacent healthy colon specimens, UC and CC contained ~ 1%, ~ 7% and ~ 7% of sequence reads, respectively that were un-assignable to any taxon with a larger proportion of them identified in AA Colitis patients. Other major phyla observed among these specimens also include Proteobacteria (Adjacent healthy: 23.8%; UC: 26.5% and CC: 23.1%), Actinobacteria (Adjacent healthy: 6.7%; UC: 8.1% and CC: 14.1%), Fusobacteria (Adjacent healthy: 4.2%; UC: 3.6% and CC: 4.0%), and Synergistetes (Adjacent healthy: 0.2%; UC: 0.04% and CC: 1.5%). The Phylum Proteobacteria did not show any significant difference between healthy colon specimens and diseased colon specimens (Table 4).

Bacterial Species Identified in a Significantly Higher Proportion in Diseased Colon Tissues

As shown in Figure 3, diseased colon specimens represented a significantly higher proportion (p < 0.05) of gut bacteria belonging to Phylum Firmicutes including Blautia producta, Faecalibacterium prausnitzii, Anoxybacillus kestanbolensis, Ruminococcus gnavus, Eubacterium dolichum, Lysinibacillus boronitolerans, and oral bacteria including Staphylococcus sciuri, Staphylococcus aureus, Streptococcus anginosus.

In contrast, healthy colon specimens were significantly dominated (p < 0.05) by oral bacteria belonging to Phylum Actinobacteria that includes; Corynebacterium kroppenstedtii, Corynebacterium durum. Additionally, healthy colon specimens were dominated by gut bacteria belonging to Phylum Actinobacteria that includes; Colinsella stercoris, Colinsella aerofaciens, Kocuria rhizophila, Eggerthella lenta, Propionibacterium granulosum, Propionibacterium acnes, Actinomyces europaeus, Rothia dentocariosa, and Phylum Bacteroidetes that includes; Bacteroides fragilis, Bacteroides eggerthii, Bacteroides caccae, Parabacteroides distasonis (Figure 3).

Alpha Diversity and Beta Diversity Analyses

Alpha diversity and beta diversity metrics were computed to analyse the diversity of bacterial species within each sample and between samples. To assess our sampling efficiency, we plotted rarefaction curves (Chao1 and Shannon) for all 39 specimens. Increased diversity (Shannon) in the diseased samples compared to control samples was observed. From the rarefaction curves, it is evident that most AA samples require additional sampling whereas Caucasian samples do not (data not shown).

Since, outliers exhibiting different microbiome profiles were observed both in the healthy and disease groups, we performed principle coordinate analysis (PCoA analysis) and hierarchial clustering to obtain a holistic view of the microbiome profile in each sample. Two dimensional PCoA plots revealed that control samples which had similar microbiome profiles as suggested by histograms and OTU heat map clustered together (data not shown).

Pathogenic Oral and Gut Flora Abundantly Colonized in Diseased Colon Specimens

The pathogenic oral bacteria identified abundantly in diseased colon specimens as compared to healthy colon specimens were Porphyromonas, Prevotella, Gemella, Staphylococcus, Streptococcus, Abiotrophia, Granulicatella, Lactobacillus, Lactococcus, Peptostreptococcus, Selenomonas, Veillonella, Parvimonas, Eubacterium, Fusobacterium, Pseudomonas, Aggregatibacter, and Corynebacterium (Table 1).

Pathogenic gut bacteria identified abundantly in diseased colon specimens as compared to healthy colon specimens include Ochrobactrum, Delftia, Sphingomonas, Burkholderia, Acinetobacter, Stenotrophomonas, Enterococcus, Granulicatella, Staphylococcus, Streptococcus, Lactobacillus, Lactococcus, Pseudomonas, Bacillus, Campylobacter, and Bacteroides (Table 3).

Discussion

Our study demonstrates significant perturbations among bacteria belonging to Phyla Bacteroidetes and Firmicutes in full-thickness diseased colon specimens containing neuromuscular compartment (Figure 2). Our studies further show that the proportion of pathogenic bacteria are higher in diseased compared to adjacent healthy colon specimens. We suggest that pathogenic bacteria belonging to these two phyla have a greater impact on colon motility function in colitis patients (Tables 1, 3). Although the incidence of IBD is increasing among African Americans (AA), the underlying causes are completely unknown (Sofia et al., 2014). Our study further highlight a significant disparity in bacterial dysbiosis among AA compared to CA colitis patients (Figure 3).

CA specimens had significantly higher levels of Fusobacterium, Parabacteroides, Citrobacter, Haemophilus, Acinetobacter, Pseudomonas, and Stenotrophomonas. Fusobacterium nucleatum is known to have a well-characterized role in the oral cavity. We have determined that Fusobacterium can be recovered from human full thickness colon specimens and this could indicate their ability to survive and proliferate inside host cells. Parabacteroides was found to be dominant in the acute phase of IBD in CA patients. Citrobacter is an epithelial cell adherent pathogen and can subvert inflammation in colitis. Pseudomonas interacts with the mucosal layer of colon and disrupts the mucosal barrier integrity leading to colitis in CA patients.

The AA specimens had significantly higher levels of Prevotella and Clostridia. Prevotella augments T-helper cells mediated colon mucosal inflammation by activating Toll-like receptor 2 leading to production of T-helper cells polarizing cytokines by antigen-presenting cells, including interleukins. In addition, Prevotella induce epithelial cells to produce interleukins and cytokines that can promote recruitment of neutrophils and mucosal T-helper cell immune responses. Prevotella can mediate inflammation of the mucosa leading to the circulation of bacteria, bacterial products and other inflammatory mediators. Prevotella could augment release of inflammatory mediators from immune cells and various stromal cells in colitis in AA patients. Clostridium can disrupt gut immune dormancy and cause infectious colitis in AA patients. Collectively, our data suggest that the presence of pathogenic bacteria in AA full thickness diseased specimens could adversely affect colon motility.

Additionally, our data in UC and CC specimens show the presence of several orange (Prevotella, Peptostreptococcus, Eubacterium, Fusobacterium, and Campylobacter), red (Porphyromonas), purple (Veillonella), and yellow (Streptococcus) complex putative oral pathogens known to cause gingivitis and periodontitis among IBD patients (Tables 1, 3). Previous studies using mucosal biopsies and feces have shown that gut microbiota in bowel diseases is characterized by an increase in certain phyla such as Proteobacteria, Firmicutes, genus Bifidobacterium, as well as a reduction in the amounts of genera Ruminococcus, Clostridia and (in some cases) Faecalibacterium (Lane et al., 2017; Nishida et al., 2018). However, none of the earlier studies using feces have shown a shift in the balance between Phyla Bacteroidetes and Firmicutes among UC or CC patients; even though this was observed in healthy individuals (Mariat et al., 2009; Koliada et al., 2017). In contrary to our results, one study using mucosal biopsies has shown a significantly decreased Firmicutes to Bacteroidetes ratio in both UC and CC compared with controls (Kabeerdoss et al., 2015). Collectively, our data suggest that the putative oral pathogens found in diseased colon specimens may modulate the proportion of non-detrimental gut bacteria, thus potentially worsening the condition of the colon in colitis patients.

Oral bacterial species like Porphyromonas, Peptostreptococcus, Eubacterium, Fusobacterium, Streptococcus salivarius, S. mitis, S. bovis, Veillonella spp., Staphylococcus aureus, S. epidermidis, and Campylobacter spp. can convert nitrate to nitrite. A large amount of bioactive NO is found in the gastrointestinal tract, generated by dietary sources and by conversion of anaerobic bacteria in the oral cavity, or by anaerobic reaction with nitrate in the colon by Escherichia coli spp. The entero-salivary nitrate conversion pathway provides a rich source of bioactive NO and nitrate-reducing bacteria, such as Veillonella. In this pathway, nitrate is obtained by the salivary gland and is then concentrated in the saliva. Various facultative anaerobic bacteria on the top of the tongue effectively reduces nitrate to nitrite. The bacteria then use the nitrate and the nitrite as electron acceptors in their respiration process. This also helps the host in the first steps of converting nitrate to NO. The salivary nitrate then reaches the systemic circulation, various enzymatic reactions occur leading to reduction to NO, and other reactive nitrogen intermediates. The oral cavity plays an important role the production of nitric oxide, and specifically, employs the nitrate-nitrite-NO pathway in the oral cavity. It is well known that oral cavity bacteria can migrate to the colon. Taken together, our data suggest that the putative oral pathogens found in diseased colon specimens may survive by exploiting the nitrate-nitrite-NO pathway to modulate the proportion of non-detrimental gut bacteria, thus potentially worsening the condition of colon in colitis patients (Figure 4).

Figure 4.

Figure 4

Schematic Representation of the suggested mechanism involved in the development of colitis by oral and gut microbiome. We propose that the increase in the concentrations of putative oral pathogens elevates the cytokine and chemokine levels in oral cavity. When putative oral pathogens travel to the gut, they can colonize locally and lead to the elevated levels of proinflammatory cytokines. This can effect on nNOS-NO-NRF2-Phase II system in the large intestine and could lead to colon dysmotility and colitis.

Previous studies suggest that enteric neurons and smooth muscle mediated gut motility is impaired in colitis patients (Snape et al., 1991; Vermillion et al., 1993). IBD associated gut inflammation affects the morphological and functional changes in the myenteric/enteric nervous system (ENS) and nitric oxide (NO) synthesis (Takahashi, 2003; Kono et al., 2004). Experimental studies have also shown that gut bacteria have a role in oxidative stress induced gut inflammation by controlling metabolic endotoxemia in obese mice (Cani et al., 2008). We have shown that polybacterial oral infection decrease the expression of nNOS and NRF2-phase II enzymes in the gut and this could lead to impaired colon motility (Gangula et al., 2015; Walker et al., 2018).

Some of the gut bacteria we have identified in the full thickness colon specimens in the present study, including Bacteroides, Prevotella, Pseudomonas, etc., have been identified in colon mucosal biopsies in earlier studies (Bibiloni et al., 2006). These bacteria evoke inflammatory responses affecting the innermost lining of colon. Many specific beneficial bacteria, including members of Bacteroides and Prevotella groups, C. coccoides, and Lactic acid bacteria were known to be decreased in colitis patients (Gibson et al., 1991). Specimens used in prior studies were colon mucosal biopsies or stool samples; but not full thickness colon specimens (Gibson et al., 1991; Bibiloni et al., 2006). Full-thickness colon consists of four layers of tissue including mucosa, submucosa, muscularis, and serosa.

Novel to this research design, full thickness colon specimens were obtained because colitis patients often experience colon motility abnormalities (Snape et al., 1991; Annese et al., 1997; Vrees et al., 2002). Several lines of evidence suggest that nitrergic neurons that releases NO via nNOS are known to play a pivotal role in colon motility (Kono et al., 2004; Winston et al., 2013). Previous studies have demonstrated that nitrergic neurons are degenerated in colitis (Onori et al., 2005; Sung et al., 2006). Recent studies from our laboratory indicate that nNOS, as well as antioxidants (NRF2 regulated-Phase II enzymes) protein expression are down-regulated in diseased colon specimens (Myers et al., 2014; Gangula et al., 2017). Furthermore, our previous studies demonstrated that polybacterial infection led to a decrease in nNOS, NRF2 and antioxidants protein expression in the colon tissues (Gangula et al., 2015). In addition, studies have shown that NO may play homeostatic role in gut inflammation (Kolios et al., 2004). Taken together, our data suggest that elevated levels of oral and gut pathogens in diseased colon full thickness specimens could contribute to impaired nNOS-NO-NRF2-Phase II system and colon motility abnormalities in IBD patients (Figure 4).

To our knowledge, our study is the first to report the presence of several microbiota of unknown function in IBD including Micrococcus luteus, Chloracidobacteria, Arthrobacter, Propionicimonas, Paludibacter, Chryseobacterium, Calothrix, and Novosphingobium (Table 5). These new microbiota members have not been identified in mucosal/fecal specimens in previous studies, suggesting that these bacteria are primarily colonized in the neuromuscular compartment. Additional studies are warranted to characterize the novel bacteria and investigate their specific role in colon motility and constipation in IBD patients.

Table 5.

Proportions of bacterial species of unknown function colonized in full thickness colon of colitis patients.

Sl. No. Bacteria genus Bacteria species Proportion (%) Bacteria phylum Function in IBD NCBI genome database link
ADJACENT HEALTHY COLON
1 Micrococcus luteus 0.01 Actinobacteria No role in IBD X
2 Arthrobacter s__ 0.01 Actinobacteria No role in IBD BL
3 Propionicimonas s__ 0.01 Actinobacteria No role in IBD BN
4 Paludibacter s__ 0.01 Bacteroidetes No role in IBD BW
5 Chryseobacterium s__ 0.02 Bacteroidetes No role in IBD CF
6 Calothrix s__ 0.03 Cyanobacteria No role in IBD CK
7 Novosphingobium s__ 0.02 Proteobacteria No role in IBD FE
DISEASED COLON (ULCERATIVE COLITIS)
1 Micrococcus luteus 0.01 Actinobacteria No role in IBD X
2 Arthrobacter s__ 0.02 Actinobacteria No role in IBD BL
3 Propionicimonas s__ 0.1 Actinobacteria No role in IBD BN
4 Paludibacter s__ 0.03 Bacteroidetes No role in IBD BW
5 Chryseobacterium s__ 0.1 Bacteroidetes No role in IBD CF
6 Calothrix s__ 0.1 Cyanobacteria No role in IBD CK
7 Novosphingobium s__ 0.04 Proteobacteria No role in IBD FE
DISEASED COLON (CROHN'S COLITIS)
1 Micrococcus luteus 0.02 Actinobacteria No role in IBD X
2 Arthrobacter s__ 0.2 Actinobacteria No role in IBD BL
3 Propionicimonas s__ 0.02 Actinobacteria No role in IBD BN
4 Paludibacter s__ 0.02 Bacteroidetes No role in IBD BW
5 Chryseobacterium s__ 0.3 Bacteroidetes No role in IBD CF
6 Calothrix s__ 0.1 Cyanobacteria No role in IBD CK
7 Novosphingobium s__ 0.01 Proteobacteria No role in IBD FE

Specific Information of functions was adapted from NCBI Genome Database (https://www.ncbi.nlm.nih.gov/genome/).

The bacterial species that could not be identified at the genus level are mentioned as g___ and the bacterial species that could not be identified at the species level are mentioned as s___.

In summary, this study have identified specific bacterial pathogens potentially associated with colon motility in IBD patients. The observations showed that some putative oral pathogens belonging to the Phyla Firmicutes (Streptococcus, Staphylococcus, Peptostreptococcus), and Fusobacteria (Fusobacterium) dominated in the microbiomes of CC and UC diseased specimens and might involve the modulation of colon motility in IBD.

Study Limitations

The limitations of the study include the smaller sample size across disease and race groups making this as a preliminary study. In spite of the limitations in sample size and the fact that some of the identified bacteria were not significantly altered in colitis specimens, we were still able to observe differences in the microbiome between CA and AA colitis patients. This could be due to amplicon sequencing of a shorter conserved region of 16S rRNA gene instead of in depth shotgun sequencing. Moreover, we did not profile the oral microbiome from oral specimens (dental plaque, etc.) in the same IBD patients from whom full thickness colon specimens were collected. Finally, host-microbiome interaction studies are needed to better discern specific roles of the oral and gut bacteria in the development of colitis. Future studies are aimed to collect oral and fecal specimens therefore a comparative experiments in regards to changes in microbiome, along with specific key proteins will be conducted from the same patient.

Author Contributions

VD, SM, KS, SP, SS, PG, and MT have contributed both for data analysis and manuscript preparation. DS, CF-D, LK, SA, and JS have contributed in manuscript preparation.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

The authors sincerely thank University of North Carolina at Chapel Hill School of Medicine- Microbiome Core Facility (UNC; MC) for performing amplicon sequencing. We thank CHTN for providing diseased and healthy specimens. We further thank dental student doctors Mr. A. Arab and J. Hodges for their initial contribution on this project. The Meharry Bioinformatics Core is funded in part by NIH grants MD007593 and MD007586. SA is supported by NIMHD R-CTR grant No. 54544MD007593 and NCI grant No. 5454CA163069. This work is supported in part by 1SC1GM121282 funded to PG. In addition, Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number SG1GM121282 (PG).

References

  1. Agossa K., Dendooven A., Dubuquoy L., Gower-Rousseau C., Delcourt-Debruyne E., Capron M. (2017). Periodontal manifestations of inflammatory bowel disease: emerging epidemiologic and biologic evidence. J. Periodontal Res. 52, 313–324. 10.1111/jre.12422 [DOI] [PubMed] [Google Scholar]
  2. Annese V., Bassotti G., Napolitano G., Usai P., Andriulli A., Vantrappen G. (1997). Gastrointestinal motility disorders in patients with inactive Crohn's disease. Scand. J. Gastroenterol. 32, 1107–1117. [DOI] [PubMed] [Google Scholar]
  3. Atarashi K., Suda W., Luo C., Kawaguchi T., Motoo I., Narushima S., et al. (2017). Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Science 358, 359–365. 10.1126/science.aan4526 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bassotti G., Antonelli E., Villanacci V., Salemme M., Coppola M., Annese V. (2014). Gastrointestinal motility disorders in inflammatory bowel diseases. World J. Gastroenterol. 20, 37–44. 10.3748/wjg.v20.i1.37 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bibiloni R., Mangold M., Madsen K. L., Fedorak R. N., Tannock G. W. (2006). The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J. Med. Microbiol. 55, 1141–1149. 10.1099/jmm.0.46498-0 [DOI] [PubMed] [Google Scholar]
  6. Cani P. D., Bibiloni R., Knauf C., Waget A., Neyrinck A. M., Delzenne N. M., et al. (2008). Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470–1481. 10.2337/db07-1403 [DOI] [PubMed] [Google Scholar]
  7. Caporaso J. G., Bittinger K., Bushman F. D., DeSantis T. Z., Andersen G. L., Knight R. (2010a). PyNAST: a flexible tool for aligning sequences to a template alignment. Bioinform. 26, 266–267. 10.1093/bioinformatics/btp636 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Caporaso J. G., Kuczynski J., Stombaugh J., Bittinger K., Bushman F. D., Costello E. K., et al. (2010b). QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335–336. 10.1038/nmeth.f.303 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Edgar R. C. (2010). Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26, 2460–2461. 10.1093/bioinformatics/btq461 [DOI] [PubMed] [Google Scholar]
  10. Gangula P., Ravella K., Chukkapalli S., Rivera M., Srinivasan S., Hale A., et al. (2015). Polybacterial periodontal pathogens alter vascular and gut BH4/nNOS/NRF2-phase II enzyme expression. PLoS ONE 10:e0129885. 10.1371/journal.pone.0129885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gangula P. R., Smoot D. T., Izban M., Ballard B., Adunyah S. (2017). Expression of NO and NRF2 enzymes in Human Colitis, in Proceedings of the RCMI Translational Science 2017 Conference (Washington, DC: ), 78. [Google Scholar]
  12. Geboes K., Collins S. (1998). Structural abnormalities of the nervous system in Crohn's disease and ulcerative colitis. Neurogastroenerol. Motil. 10, 189–202. [DOI] [PubMed] [Google Scholar]
  13. Gibson G. R., Cummings J. H., Macfarlane G. T. (1991). Growth and activities of sulphate-reducing bacteria in gut contents of healthy subjects and patients with ulcerative colitis. FEMS Microbiol. Lett. 86, 103–111. 10.1111/j.1574-6968.1991.tb04799.x [DOI] [Google Scholar]
  14. Gower J. C. (2005). Principal coordinates analysis, in Encyclopedia of Biostatistics, eds Armitage P., Colton T. (John Wiley & Sons Ltd) 10.1002/0470011815 [DOI] [Google Scholar]
  15. Haas B. J., Gevers D., Earl A. M., Feldgarden M., Ward D. V., Giannoukos G., et al. (2011). Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res. 21, 494–504. 10.1101/gr.112730.110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hajishengallis G. (2015). Periodontitis: from microbial immune subversion to systemic inflammation. Nat. Rev. Immunol. 15, 30–44. 10.1038/nri3785 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kabeerdoss J., Jayakanthan P., Pugazhendhi S., Ramakrishna B. S. (2015). Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid. Indian J Med Res. 142, 23–32. 10.4103/0971-5916.162091 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Keegan K. P., Glass E. M., Meyer F. (2016). MG-RAST, a metagenomics service for analysis of microbial community structure and function. Methods Mol. Biol. 1399, 207–233. 10.1007/978-1-4939-3369-3_13 [DOI] [PubMed] [Google Scholar]
  19. Koliada A., Syzenko G., Moseiko V., Budovska L., Puchkov K., Perederiy V., et al. (2017). Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. BMC Microbiol. 17:120. 10.1186/s12866-017-1027-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kolios G., Valatas V., Ward S. G. (2004). Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology 113, 427–437. 10.1111/j.1365-2567.2004.01984.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kono T., Chisato N., Ebisawa Y., Asama T., Sugawara M., Ayabe T., et al. (2004). Impaired nitric oxide production of the myenteric plexus in colitis detected by a new bioimaging system. J. Surg. Res. 117, 329–336. 10.1016/j.jss.2003.11.004 [DOI] [PubMed] [Google Scholar]
  22. Lane E. R., Zisman T. L., Suskind D. L. (2017). The microbiota in inflammatory bowel disease: current and therapeutic insights. J. Inflamm. Res. 10, 63–73. 10.2147/JIR.S116088 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lira-Junior R., Figueredo C. M. (2016). Periodontal and inflammatory bowel diseases: is there evidence of complex pathogenic interactions? World J. Gastroenterol. 22, 7963–7972. 10.3748/wjg.v22.i35.7963 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mariat D., Firmesse O., Levenez F., Guimaraes V. D., Sokol H., Dore J., et al. (2009). The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 9:123. 10.1186/1471-2180-9-123 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Myers J. N., Schaffer M. W., Korolkova O. Y., Williams A. D., Gangula P. R., M'Koma A. E. (2014). Implications of the colonic deposition of free hemoglobin-α chain: a previously unknown tissue by-product in inflammatory bowel disease. Inflamm. Bowel Dis. 20, 1530–1547. 10.1097/MIB.0000000000000144 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Nishida A., Inoue R., Inatomi O., Bamba S., Naito Y., Andoh A. (2018). Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin. J. Gastroenterol. 11, 1–10. 10.1007/s12328-017-0813-5 [DOI] [PubMed] [Google Scholar]
  27. Onori L., Aggio A., D'Alo S., Muzi P., Cifone M. G., Mellillo G., et al. (2005). Role of nitric oxide in the impairment of circular muscle contractility of distended, uninflamed mid-colon in TNBS-induced acute distal colitis in rats. World J. Gastroenterol. 11, 5677–5684. 10.3748/wjg.v11.i36.5677 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Poli E., Lazzeretti M., Grandi D., Pozzoli C., Coruzzi G. (2001). Morphological and functional alterations of the myenteric plexus in rats with TNBS-induced colitis. Neurochem. Res. 26, 1085–1093. 10.1023/A:1012313424144 [DOI] [PubMed] [Google Scholar]
  29. Popova C., Dosseva-Panova V., Panov V. (2013). Microbiology of periodontal diseases. a review. Biotechnol. Biotechnol. Equip. 27, 3754–3759. 10.5504/BBEQ.2013.0027 [DOI] [Google Scholar]
  30. Price M. N., Dehal P. S., Arkin A. P. (2010). FastTree 2-approximately maximum-likelihood trees for large alignments. PLoS ONE 5:e9490. 10.1371/journal.pone.0009490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Schloss P. D., Westcott S. L., Ryabin T., Hall J. R., Hartmann M., Hollister E. B., et al. (2009). Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. 75, 7537–7541. 10.1128/AEM.01541-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Snape W. J., Jr., Williams R., Hyman P. E. (1991). Defect in colonic smooth muscle contraction in patients with ulcerative colitis. Am. J. Physiol. 261, G987–G991. 10.1152/ajpgi.1991.261.6.G987 [DOI] [PubMed] [Google Scholar]
  33. Sofia M. A., Rubin D. T., Hou N., Pekow J. (2014). Clinical presentation and disease course of inflammatory bowel disease differs by race in a large tertiary care hospital. Dig Dis Sci. 59, 2228–2235. 10.1007/s10620-014-3160-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Strauss J., Kaplan G. G., Beck P. L., Rioux K., Panaccione R., Devinney R., et al. (2011). Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm. Bowel Dis. 17, 1971–1978. 10.1002/ibd.21606 [DOI] [PubMed] [Google Scholar]
  35. Sung T. S., La J. H., Kim T. W., Yang I. S. (2006). Alteration of nitrergic neuromuscular transmission as a result of acute experimental colitis in rat. J. Vet. Sci. 7, 143–150. 10.4142/jvs.2006.7.2.143 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Takahashi T. (2003). Pathophysiological significance of neuronal nitric oxide synthase in the gastrointestinal tract. J. Gastroenterol. 38, 421–430. 10.1007/s00535-003-1094-y [DOI] [PubMed] [Google Scholar]
  37. Vavricka S. R., Manser C. N., Hediger S., Vogelin M., Scharl M., Biedermann L., et al. (2013). Periodontitis and gingivitis in inflammatory bowel disease: a case-control study. Inflamm. Bowel. Dis. 19, 2768–2777. 10.1097/01.MIB.0000438356.84263.3b [DOI] [PubMed] [Google Scholar]
  38. Vermillion D. L., Huizinga J. D., Riddell R. H., Collins S. M. (1993). Altered small intestinal smooth muscle function in Crohn's disease. Gastroenterol. 104, 1692–1699. [DOI] [PubMed] [Google Scholar]
  39. Vrees M. D., Pricolo V. E., Ptenti F. M., Cao W. (2002). Abnormal motility in patients with ulcerative colitis: the role of inflammatory cytokines. Arch. Surg. 137, 439–445. 10.1001/archsurg.137.4.439 [DOI] [PubMed] [Google Scholar]
  40. Walker M. Y., Pratap S., Southerland J. H., Farmer-Dixon C. M., Lakshmyya K., Gangula P. R. (2018). Role of oral and gut microbiome in nitric oxide-mediated colon motility. Nitric Oxide 73, 81–88. 10.1016/j.niox.2017.06.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Winston J. H., Li Q., Sarna S. K. (2013). Paradoxical regulation of ChAT and nNOS expression in animal models of Crohn's colitis and ulcerative colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 305, G295–302. 10.1152/ajpgi.00052.2013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Zhao L., Huang Y., Lu L., Yang W., Huang T., Lin Z., et al. (2018). Saturated long-chain fatty acid-producing bacteria contribute to enhanced colonic motility in rats. Microbiome 6:107. 10.1186/s40168-018-0492-6 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Microbiology are provided here courtesy of Frontiers Media SA

RESOURCES